Study #2021-0897
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
MD Anderson Study Status
Not Accepting
Treatment Agent
sapablursen
Description
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Phlebotomy Dependent Polycythemia Vera
Study phase:
Phase II
Physician name:
Prithviraj Bose
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.